)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Milestone Pharmaceuticals
Milestone Pharmaceuticals (MIST) investor relations material
Milestone Pharmaceuticals H.C. Wainwright 28th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference summary15 Sep, 2026
Key achievements and recent progress
Achieved FDA approval for a new drug in December and launched it aggressively by mid-February, establishing a field force and promotional materials quickly.
Initiated a phase III study for a second indication, atrial fibrillation with rapid ventricular rate, with the first patient enrolled last month.
Focused on execution for both the ongoing drug launch and the AFib program, with a two-year timeline to data for the latter.
Early market feedback from healthcare providers has been very positive, especially regarding the drug's rapid action and safety profile.
Patient feedback is emerging, with momentum expected to build as awareness increases.
Market adoption and prescriber behavior
Initial prescriptions are primarily for newly diagnosed or highly engaged patients, especially those with recent emergency department visits.
Promotional response among doctors has exceeded expectations, with engagement accelerating as awareness grows.
Most patients have tried other treatments before, and broader adoption requires breaking established habits through repeat detailing and patient activation.
Refills are trending up, with refill rates currently between 15% and 20%, expected to rise significantly as patients gain experience.
Deeper prescriber adoption and increased refills are anticipated to accelerate in the coming year.
Electrophysiologist engagement and influence
Electrophysiologists have adopted the drug faster than expected, driven by their role as thought leaders and their affinity for new technology.
The drug is seen as complementary to ablation procedures, providing a bridge for patients awaiting ablation or those not opting for it.
Promotional response is higher among electrophysiologists than clinical cardiologists, aiding institutional adoption and potential guideline updates.
Early adoption by electrophysiologists is valuable for broader market acceptance and influence on practice patterns.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Milestone Pharmaceuticals
- Strong launch momentum, expanding coverage, and a robust pipeline drive future growth.MIST
Wells Fargo 21st Annual Healthcare Conference - CARDAMYST launches as the first new PSVT therapy in 30+ years, targeting a $5B+ US market.MISTCorporate presentation
- CARDAMYST launch spurred rapid adoption, expanded coverage, and higher launch-driven net loss.MISTQ2 2026
- CARDAMYST launches as a first-in-class PSVT therapy, backed by strong data and financials.MISTCorporate presentation
- CARDAMYST sees strong early adoption, payer traction, and plans for AFib trials and real-world data registry.MISTH.C. Wainwright 4th Annual BioConnect Investor Conference
- CARDAMYST launches as the first new PSVT therapy in decades, targeting broad adoption and expansion into AFib-RVR.MISTCorporate presentation
- Mid-2025 launch planned, targeting high-value prescribers and rapid at-home PSVT relief.MISTInvestor update
- FDA approved first self-administered nasal spray for PSVT, launching Q1 2026.MISTFDA Announcement
- Etripamil nears FDA approval, offering rapid relief for PSVT and AFib-RVR with strong market prospects.MISTTD Cowen 45th Annual Healthcare Conference
Next Milestone Pharmaceuticals earnings date
Q3 202613 Nov, 2026
Milestone Pharmaceuticals
Next Milestone Pharmaceuticals earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing cardiovascular therapies. The company specializes in the research and development of treatments for episodic cardiovascular conditions, aiming to provide rapid and effective symptom relief. Its lead drug candidates target conditions such as paroxysmal supraventricular tachycardia (PSVT) and other heart-related disorders. The company is headquartered in Montreal, Canada, and its shares are listed on the NASDAQ.